Evidence map›Paper›PMID 41862522›Full record

ArticleScientific reports2026

Nanomotion-enabled ultra-rapid antibiotic susceptibility testing with magnetic bead-based pathogen enrichment for accelerated sepsis diagnostics.

Grzegorz Jóźwiak, Marta Pla Verge, Amanda Luraschi-Eggemann, Cyrine Mestiri, Elinor McSorley, Daisy Wilson-Owen, Sonia La Fauci, María García-Castillo, Eric Delarze, Katja Fromm and 18 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Rapid delineation ofMicrobiology spectrum · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Grzegorz JóźwiakResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Marta Pla VergeResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Amanda Luraschi-EggemannResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Cyrine MestiriMomentum Bioscience Milton Park, Oxfordshire, UK.
Elinor McSorleyMomentum Bioscience Milton Park, Oxfordshire, UK.
Daisy Wilson-OwenMomentum Bioscience Milton Park, Oxfordshire, UK.
Sonia La FauciMomentum Bioscience Milton Park, Oxfordshire, UK.
María García-CastilloHospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Eric DelarzeResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Katja FrommResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Laura MunchResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Caspar VogelResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Dimitrios BalasopoulosResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Gino CathomenResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Silke ReiterResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Michał ŚwiątkowskiResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Roxana TotuResistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Susanne HäusslerHelmholtz Centre for Infection Research, Braunschweig, Germany.
Tanel TensonInstitute of Technology, University of Tartu, Tartu, Estonia.
Stefano PagliaraLiving Systems Institute and Biosciences, University of Exeter, Exeter, UK.
Rafael CantónHospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Gilbert GreubInstitute of Microbiology, Lausanne University Hospital & University of Lausanne, Lausanne, Switzerland.
Gorm LisbyDepartment of Clinical Microbiology, Hvidovre Hospital, Copenhagen, Denmark.
William MullenMomentum Bioscience Milton Park, Oxfordshire, UK.
Daniel LockhartMomentum Bioscience Milton Park, Oxfordshire, UK.
Danuta Cichocka *Resistell AG, Hofackerstrasse 40, Muttenz, Switzerland.
Alexander Sturm *Resistell AG, Hofackerstrasse 40, Muttenz, Switzerland. alex.sturm@resistell.com.
ERADIAMR consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid and accurate antimicrobial susceptibility testing (AST) is critical for guiding therapy in life-threatening infections such as sepsis, but current diagnostics rely on blood culture, delaying results by 48–72 h. This time lag forces empirical use of broad-spectrum antibiotics, increasing risks of treatment failure and antimicrobial resistance. We developed an approach combining bacterial growth-independent nanomotion detection with magnetic bead–based enrichment directly from blood. Using machine-learning classifiers trained on nanomotion spectra, we established ten antibiotic-specific models across 1,337 blood culture samples containing 390 clinical isolates of Enterobacterales (e.g., Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae) and Pseudomonas aeruginosa. These models achieved 94–98% sensitivity and specificity with fixed 2-h readouts. In parallel, SepsiSTAT enrichment enabled rapid recovery of viable bacteria and yeast at clinically relevant concentrations from 10 mL blood, with time-to-positivity averaging 5.5 h, i.e., over 7 h faster and more predictable than conventional blood culturing. The workflow was afterwards adapted to 1 mL input volumes, compatible with blood volume sampling constraints in fragile patient groups such as geriatric or neonatal patients. In spiked E. coli blood samples, ceftriaxone susceptibility was determined within 9–11 h of collection, nearly two days earlier than current standards. By integrating enrichment with nanomotion AST, we introduce a low-volume, label-free, phenotypic diagnostic platform capable of delivering actionable results within clinically meaningful timeframes. This approach holds potential to improve antibiotic stewardship, enable earlier transition from empiric to targeted therapy, and expand diagnostic access for vulnerable populations such as neonates.

Indexed as

Anti-Bacterial AgentsSepsisEscherichia coliHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsAMRAntibiotic susceptibility testBacteremiaBlood cultureBloodstream infectionInfectious diseaseMagnetic bead enrichmentNanomotionsSepsisSepticemia

Identifiers

PMID41862522
PMCPMC13194865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.